Chordoma Foundation


Clinical Trials

This page lists all open clinical trials that are specifically recruiting chordoma patients.

Clinical trials give patients an opportunity to receive new, experimental treatments that have the potential to offer more benefit than clinically available alternatives, or to receive clinically available treatments at no cost. In addition to having the potential to benefit from the latest treatments, chordoma patients who participate in clinical trials contribute to knowledge that can guide therapy for future patients and potentially help identify new ways of treating this rare cancer. Before enrolling in a clinical trial it is important to understand the potential risks and benefits, and to discuss your options with your physicians.

Identifier


Treatment


Setting


Phase


Mechanism


Target


Locations


NCT01407198 Nilotinib plus radiation High risk disease Phase I Radiation sensitization with multikinase inhibitor PDGFR Massachusetts General Hospital
NCT01924689 Clostridium Novyi-NT Advanced tumor, no direct bone involvement Phase I Controlled infection of tumor by tumor-seeking bacteria (“biosurgery”) plus induced immune response Hyptoxia Memorial Sloan Kettering, MD Anderson, University of Michigan
NCT02179515 MVA-Brachyury-TRICOM Unresectable, locally recurrent, or metastatic tumor Phase I Induced immune response to cells expressing the brachyury protein Brachyury National Cancer Institute

To receive email updates about new clinical trials that are open to chordoma patients, sign up here.

Useful Information About Clinical Trials


The Chordoma Foundation cannot guarantee the completeness of this list of clinical trials. For more information about clinical trials that you might qualify for, consult with your physician or visit www.clinicaltrials.gov. Please contact us if you are aware of additional clinical trials open to chordoma patients.